tiprankstipranks
Advertisement
Advertisement

AU:CUV Stock Latest News

Clinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review
Company AnnouncementsClinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review
6d ago
FDA Drops QT Study Requirement for Clinuvel’s SCENESSE
PremiumCompany Announcements
FDA Drops QT Study Requirement for Clinuvel’s SCENESSE
7d ago
Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE
PremiumCompany Announcements
Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE
10d ago
Clinuvel Performance Rights Lapse After Conditions Not Met
PremiumCompany Announcements
Clinuvel Performance Rights Lapse After Conditions Not Met
17d ago
Clinuvel Issues New Shares, Confirms Compliance With Disclosure Rules
PremiumCompany Announcements
Clinuvel Issues New Shares, Confirms Compliance With Disclosure Rules
21d ago
Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
PremiumCompany AnnouncementsClinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
1M ago
Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting
Premium
Company Announcements
Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting
1M ago
Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push
Premium
Company Announcements
Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push
2M ago
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
PremiumCompany Announcements
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
2M ago
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
PremiumCompany Announcements
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
3M ago
Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
PremiumCompany Announcements
Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
4M ago
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
PremiumCompany Announcements
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
4M ago
Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights
PremiumCompany AnnouncementsClinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights
4M ago
Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting
Premium
Company Announcements
Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting
5M ago
CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies
Premium
Company Announcements
CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies
5M ago
CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant
PremiumCompany Announcements
CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant
5M ago
Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus
PremiumCompany Announcements
Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus
6M ago
CLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown
PremiumCompany Announcements
CLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown
6M ago
Clinuvel Pharmaceuticals Emphasizes Strategic Cash Utilization for Sustained Growth
PremiumCompany Announcements
Clinuvel Pharmaceuticals Emphasizes Strategic Cash Utilization for Sustained Growth
7M ago
Clinuvel Pharmaceuticals: Strategic Execution and Growth at 2025 AGM
PremiumCompany AnnouncementsClinuvel Pharmaceuticals: Strategic Execution and Growth at 2025 AGM
7M ago
Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP
Premium
Company Announcements
Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP
7M ago
CLINUVEL Pharmaceuticals Issues New Shares to Strengthen Market Position
Premium
Company Announcements
CLINUVEL Pharmaceuticals Issues New Shares to Strengthen Market Position
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >